Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study Oral Contraceptives and the Risk of Ischemic Stroke

Background and Purpose — Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contrace...

Full description

Saved in:
Bibliographic Details
Published inStroke (1970) Vol. 33; no. 5; pp. 1202 - 1208
Main Authors Kemmeren, Jeanet M., Tanis, Bea C., van den Bosch, Maurice A.A.J., Bollen, Edward L.E.M., Helmerhorst, Frans M., van der Graaf, Yolanda, Rosendaal, Frits R., Algra, Ale
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 01.05.2002
American Heart Association, Inc
Subjects
Online AccessGet full text
ISSN0039-2499
1524-4628
1524-4628
DOI10.1161/01.STR.0000015345.61324.3F

Cover

Abstract Background and Purpose — Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. Methods — A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors. Results — Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8). Conclusions — Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).
AbstractList Background and Purpose — Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. Methods — A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors. Results — Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8). Conclusions — Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).
Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives.BACKGROUND AND PURPOSEEpidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives.A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors.METHODSA multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors.Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8).RESULTSTwo hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8).Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).CONCLUSIONSThird-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).
BACKGROUND AND PURPOSE: Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. METHODS: A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors. RESULTS: Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8). CONCLUSIONS: Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).
Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors. Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8). Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).
Author van den Bosch, Maurice A.A.J.
Kemmeren, Jeanet M.
Helmerhorst, Frans M.
Bollen, Edward L.E.M.
van der Graaf, Yolanda
Tanis, Bea C.
Algra, Ale
Rosendaal, Frits R.
Author_xml – sequence: 1
  givenname: Jeanet M.
  surname: Kemmeren
  fullname: Kemmeren, Jeanet M.
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 2
  givenname: Bea C.
  surname: Tanis
  fullname: Tanis, Bea C.
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 3
  givenname: Maurice A.A.J.
  surname: van den Bosch
  fullname: van den Bosch, Maurice A.A.J.
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 4
  givenname: Edward L.E.M.
  surname: Bollen
  fullname: Bollen, Edward L.E.M.
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 5
  givenname: Frans M.
  surname: Helmerhorst
  fullname: Helmerhorst, Frans M.
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 6
  givenname: Yolanda
  surname: van der Graaf
  fullname: van der Graaf, Yolanda
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 7
  givenname: Frits R.
  surname: Rosendaal
  fullname: Rosendaal, Frits R.
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
– sequence: 8
  givenname: Ale
  surname: Algra
  fullname: Algra, Ale
  organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13659553$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11988591$$D View this record in MEDLINE/PubMed
BookMark eNqF0U9rFDEYBvAgFbutfgUZCko9zJg3_zbpyWXpamFhYbueQyaTwdTZyZpkhH5703a10Iu55JBfnoT3OUMnYxgdQheAGwABnzE0t7ttgx8WcMp4I4AS1tDVKzQDTljNBJEnaIYxVTVhSp2is5TuCidU8jfoFEBJyRXM0Hrr088q9NUiZhe9Gardjxj2bUg-VX6stm4w2YexyqHaxHK8DGOOxrpD9r9dqi63i93N5lN1m6fu_i163ZshuXfH_Rx9X13vlt_q9ebrzXKxri1lONdWWNYRB1gI0rdYEkZa4F1nQTDFmJsLK2nXgbK4BSt5zwEr5VrLqeyI7ek5-viUe4jh1-RS1nufrBsGM7owJT0vQZQrUuDFC3gXpjiWv2lQc0mlpKqg90c0tXvX6UP0exPv9d8hFfDhCEyyZuijGa1Pz44KrjinxX15cjaGlKLrtfX5cXplYn7QgPVDfxqDLv3p5_70Y3-arkrE1YuIf6_8__If8smdDQ
CODEN SJCCA7
CitedBy_id crossref_primary_10_1016_j_thromres_2003_10_019
crossref_primary_10_1097_NRL_0000000000000226
crossref_primary_10_1016_j_contraception_2008_07_024
crossref_primary_10_2217_17455057_1_1_133
crossref_primary_10_1186_s12872_019_1040_4
crossref_primary_10_15585_mmwr_rr7304a1
crossref_primary_10_1097_01_AOG_0000172428_78411_b0
crossref_primary_10_1017_S0317167100003620
crossref_primary_10_3109_13625187_2014_960561
crossref_primary_10_1016_j_lpm_2011_02_035
crossref_primary_10_1111_j_1743_6109_2012_02876_x
crossref_primary_10_1007_s00404_016_4143_5
crossref_primary_10_1111_head_12035
crossref_primary_10_1111_j_1538_7836_2005_01690_x
crossref_primary_10_3389_fneur_2019_00993
crossref_primary_10_1002_14651858_CD011054_pub2
crossref_primary_10_1212_CON_0000000000001237
crossref_primary_10_1210_en_2018_00465
crossref_primary_10_1111_acem_13243
crossref_primary_10_1177_1076029612440036
crossref_primary_10_1016_j_maturitas_2016_02_008
crossref_primary_10_1016_j_atherosclerosis_2012_04_024
crossref_primary_10_1016_j_maturitas_2011_12_010
crossref_primary_10_15585_mmwr_mm6618a5
crossref_primary_10_1007_s00404_011_2190_5
crossref_primary_10_1046_j_1538_7836_2003_00162_x
crossref_primary_10_1111_bjh_14043
crossref_primary_10_1182_asheducation_V2005_1_1_1
crossref_primary_10_1046_j_1538_7836_2003_00264_x
crossref_primary_10_1007_s11886_013_0374_2
crossref_primary_10_1016_S0741_5214_02_75465_7
crossref_primary_10_2217_fnl_09_66
crossref_primary_10_1016_j_reuma_2009_01_012
crossref_primary_10_1016_j_rdc_2016_12_001
crossref_primary_10_1182_blood_2011_12_395889
crossref_primary_10_1212_01_CON_0000300025_15285_92
crossref_primary_10_1111_j_1365_2141_2011_08935_x
crossref_primary_10_1097_00008571_200310000_00002
crossref_primary_10_1056_NEJMcp030751
crossref_primary_10_1016_j_fertnstert_2009_08_052
crossref_primary_10_1038_ncprheum0484
crossref_primary_10_1016_j_ajog_2005_12_045
crossref_primary_10_1016_j_clindermatol_2009_03_006
crossref_primary_10_20473_imhsj_v3i1_2019_37_50
crossref_primary_10_2165_00023210_200620020_00004
crossref_primary_10_1016_j_contraception_2005_08_005
crossref_primary_10_1016_j_thromres_2015_04_021
crossref_primary_10_1517_17455057_1_1_133
crossref_primary_10_1016_j_ijoa_2007_10_005
crossref_primary_10_1177_1756286420985237
crossref_primary_10_1016_j_jaut_2011_11_002
crossref_primary_10_1016_j_beem_2012_11_003
crossref_primary_10_1111_j_1538_7836_2012_04927_x
crossref_primary_10_1016_S1634_7072_16_80383_9
crossref_primary_10_1007_s11055_018_0610_8
crossref_primary_10_1016_j_thromres_2015_04_013
crossref_primary_10_1002_pds_663
crossref_primary_10_1097_01_PGO_0000316647_92408_1b
crossref_primary_10_1097_FPC_0b013e328338f54f
crossref_primary_10_1089_152460902760277921
crossref_primary_10_22270_jddt_v10i6_s_4494
crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107624
crossref_primary_10_1016_j_fertnstert_2006_08_012
crossref_primary_10_1016_S1474_4422_09_70239_X
crossref_primary_10_1007_s11883_010_0118_3
crossref_primary_10_17116_jnevro20171171270_74
crossref_primary_10_1177_1591019918782964
crossref_primary_10_1016_j_fertnstert_2004_07_935
crossref_primary_10_1016_S1701_2163_16_30260_2
crossref_primary_10_1177_875512251102700504
crossref_primary_10_1182_blood_2007_08_110254
crossref_primary_10_1186_s12905_021_01305_5
crossref_primary_10_2217_17455057_3_3_369
crossref_primary_10_1111_j_1526_4610_2011_02051_x
crossref_primary_10_1016_j_osfp_2011_03_001
crossref_primary_10_1016_S0377_1237_08_80021_4
crossref_primary_10_1080_15265161_2014_919364
crossref_primary_10_1097_GCO_0b013e32821642e6
crossref_primary_10_1182_blood_2011_09_380618
crossref_primary_10_1007_s11239_014_1077_2
crossref_primary_10_1111_jth_14307
crossref_primary_10_1186_1471_2261_6_40
crossref_primary_10_1556_OH_2011_29201
crossref_primary_10_1038_clpt_2009_29
crossref_primary_10_1016_j_mayocp_2020_08_045
crossref_primary_10_1007_s11940_018_0492_7
crossref_primary_10_1177_1358863X16668263
crossref_primary_10_1097_NRL_0b013e318191f600
crossref_primary_10_1111_j_1538_7836_2008_03266_x
crossref_primary_10_1590_0034_7167_2016_0056
crossref_primary_10_1016_S1957_2557_08_74040_9
crossref_primary_10_1002_jcph_637
crossref_primary_10_1177_147470491301100315
crossref_primary_10_3724_SP_J_1008_2011_01282
crossref_primary_10_1111_jth_12531
crossref_primary_10_1007_s11239_007_0180_z
crossref_primary_10_1111_1471_0528_14358
crossref_primary_10_1111_jth_13109
crossref_primary_10_1111_head_13796
crossref_primary_10_1007_s15202_015_0641_8
crossref_primary_10_1016_j_fertnstert_2004_03_019
crossref_primary_10_1016_S1701_2163_16_30261_4
crossref_primary_10_1080_14787210_2020_1757430
crossref_primary_10_1007_s11940_008_0049_2
crossref_primary_10_1016_j_contraception_2016_05_014
crossref_primary_10_1111_ejh_14061
crossref_primary_10_1182_asheducation_2005_1_1
crossref_primary_10_1016_j_fertnstert_2008_08_093
crossref_primary_10_1016_j_medcli_2010_05_020
crossref_primary_10_1783_147118907781004750
crossref_primary_10_1007_s11926_021_01006_w
crossref_primary_10_1136_bcr_2012_008055
crossref_primary_10_1111_j_1538_7836_2005_01442_x
crossref_primary_10_1016_j_jns_2003_08_012
crossref_primary_10_1016_S0246_0378_06_38887_2
crossref_primary_10_1016_j_expneurol_2014_02_011
crossref_primary_10_1016_S1474_4422_05_70220_9
crossref_primary_10_1016_j_contraception_2012_09_023
crossref_primary_10_1016_j_mcna_2015_01_007
crossref_primary_10_1016_j_jaad_2007_12_040
crossref_primary_10_1136_bmjsrh_2019_OOC
crossref_primary_10_25692_ACEN_2019_3_2
crossref_primary_10_1016_j_ncl_2008_05_009
crossref_primary_10_1177_0024363918813579
crossref_primary_10_1586_17474108_3_2_189
crossref_primary_10_1093_humupd_dml028
crossref_primary_10_4103_0022_3859_147036
crossref_primary_10_1530_EJE_13_0493
crossref_primary_10_1007_s10227_004_0755_7
crossref_primary_10_1007_s11154_011_9178_0
crossref_primary_10_1016_S2173_5743_10_70008_3
crossref_primary_10_2165_00023210_200519080_00004
crossref_primary_10_1016_j_ando_2009_12_001
crossref_primary_10_1016_j_ando_2009_12_002
crossref_primary_10_1097_MBC_0b013e32833b2b84
crossref_primary_10_1111_jth_13045
crossref_primary_10_1016_S0246_1064_09_46119_X
crossref_primary_10_1111_j_1365_2141_2009_07805_x
Cites_doi 10.1111/j.1471-0528.1994.tb13578.x
10.1016/S0010-7824(97)00204-7
10.7326/0003-4819-72-1-111
10.1093/oxfordjournals.aje.a114869
10.1136/bmj.2.5965.241
10.7326/0003-4819-127-8_Part_1-199710150-00003
10.1016/S0010-7824(98)00032-8
10.1056/NEJMoa003216
10.1016/0010-7824(94)90106-6
10.1001/jama.1975.03240190022010
10.1016/S0140-6736(95)91929-5
10.1111/j.1471-0528.1998.tb10235.x
10.1016/S0140-6736(95)12393-8
10.7326/0003-4819-89-1-58
10.1001/archneur.1995.00540280029015
10.1093/oxfordjournals.aje.a113955
10.1093/oxfordjournals.aje.a116946
10.1016/S0140-6736(99)01013-2
10.1056/NEJM199607043350102
10.1182/blood.V89.8.2817
10.1161/str.26.3.361
10.1136/bmj.312.7023.83
10.1016/S0140-6736(95)91928-7
10.1016/S0140-6736(95)91926-0
ContentType Journal Article
Copyright 2002 INIST-CNRS
Copyright American Heart Association, Inc. May 2002
Copyright_xml – notice: 2002 INIST-CNRS
– notice: Copyright American Heart Association, Inc. May 2002
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DOI 10.1161/01.STR.0000015345.61324.3F
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
ProQuest Nursing and Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4628
EndPage 1208
ExternalDocumentID 124797781
11988591
13659553
10_1161_01_STR_0000015345_61324_3F
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GeographicLocations Netherlands
Europe
GeographicLocations_xml – name: Netherlands
GroupedDBID ---
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
123
1J1
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5RE
5VS
6PF
71W
77Y
7O~
A9M
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AAQQT
AARTV
AASCR
AASOK
AAUEB
AAXQO
AAYEP
AAYJJ
AAYXX
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACDOF
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADGHP
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFDTB
AFEXH
AFFNX
AFMBP
AFNMH
AFSOK
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BCGUY
BOYCO
BQLVK
BS7
C45
CITATION
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
M18
N4W
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB3
OCUKA
ODA
ODMTH
OGROG
OHYEH
OK1
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YHZ
YQJ
YYP
ZB8
ZGI
ZZMQN
IQODW
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OJAPA
OLW
RHF
YCJ
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c340t-c6c4d2e10662fb08242b15ddc164944e76c83dd19c0b1c85f51099ebc538d2cf3
ISSN 0039-2499
1524-4628
IngestDate Fri Jul 11 12:04:54 EDT 2025
Mon Jun 30 03:18:38 EDT 2025
Wed Feb 19 02:36:03 EST 2025
Mon Jul 21 09:11:27 EDT 2025
Tue Jul 01 01:13:40 EDT 2025
Thu Apr 24 22:56:23 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Human
Nervous system diseases
Oral administration
Cardiovascular disease
Route of administration
Epidemiology
Thrombosis
Artery
Cerebral disorder
Arterial disease
Vascular disease
Ischemia
Central nervous system disease
Risk factor
Contraceptive
Cerebrovascular disease
Brain (vertebrata)
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c340t-c6c4d2e10662fb08242b15ddc164944e76c83dd19c0b1c85f51099ebc538d2cf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 11988591
PQID 197838839
PQPubID 35232
PageCount 7
ParticipantIDs proquest_miscellaneous_71643592
proquest_journals_197838839
pubmed_primary_11988591
pascalfrancis_primary_13659553
crossref_citationtrail_10_1161_01_STR_0000015345_61324_3F
crossref_primary_10_1161_01_STR_0000015345_61324_3F
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2002-05-01
PublicationDateYYYYMMDD 2002-05-01
PublicationDate_xml – month: 05
  year: 2002
  text: 2002-05-01
  day: 01
PublicationDecade 2000
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
– name: Hagerstown
PublicationTitle Stroke (1970)
PublicationTitleAlternate Stroke
PublicationYear 2002
Publisher Lippincott Williams & Wilkins
American Heart Association, Inc
Publisher_xml – name: Lippincott Williams & Wilkins
– name: American Heart Association, Inc
References (e_1_3_3_6_2) 1963; 1
(e_1_3_3_7_2) 1961; 2
e_1_3_3_17_2
e_1_3_3_16_2
e_1_3_3_19_2
(e_1_3_3_15_2) 1998; 351
e_1_3_3_18_2
e_1_3_3_13_2
e_1_3_3_12_2
e_1_3_3_14_2
e_1_3_3_11_2
e_1_3_3_10_2
(e_1_3_3_2_2) 1962; 2
e_1_3_3_5_2
e_1_3_3_28_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_26_2
e_1_3_3_25_2
e_1_3_3_20_2
e_1_3_3_1_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_3_2
(e_1_3_3_8_2) 1993; 81
e_1_3_3_21_2
References_xml – ident: e_1_3_3_9_2
  doi: 10.1111/j.1471-0528.1994.tb13578.x
– ident: e_1_3_3_17_2
  doi: 10.1016/S0010-7824(97)00204-7
– ident: e_1_3_3_3_2
  doi: 10.7326/0003-4819-72-1-111
– ident: e_1_3_3_23_2
  doi: 10.1093/oxfordjournals.aje.a114869
– ident: e_1_3_3_24_2
  doi: 10.1136/bmj.2.5965.241
– ident: e_1_3_3_29_2
  doi: 10.7326/0003-4819-127-8_Part_1-199710150-00003
– ident: e_1_3_3_18_2
  doi: 10.1016/S0010-7824(98)00032-8
– ident: e_1_3_3_20_2
  doi: 10.1056/NEJMoa003216
– volume: 81
  start-page: 1034
  year: 1993
  ident: e_1_3_3_8_2
  publication-title: Obstet Gynecol
– volume: 1
  start-page: 111.
  year: 1963
  ident: e_1_3_3_6_2
  publication-title: Lancet
– ident: e_1_3_3_10_2
  doi: 10.1016/0010-7824(94)90106-6
– volume: 2
  start-page: 1146
  year: 1961
  ident: e_1_3_3_7_2
  publication-title: Lancet
– ident: e_1_3_3_4_2
  doi: 10.1001/jama.1975.03240190022010
– ident: e_1_3_3_13_2
  doi: 10.1016/S0140-6736(95)91929-5
– volume: 351
  start-page: 1404.
  year: 1998
  ident: e_1_3_3_15_2
  publication-title: Lancet
– ident: e_1_3_3_27_2
  doi: 10.1111/j.1471-0528.1998.tb10235.x
– ident: e_1_3_3_16_2
  doi: 10.1016/S0140-6736(95)12393-8
– ident: e_1_3_3_5_2
  doi: 10.7326/0003-4819-89-1-58
– ident: e_1_3_3_26_2
  doi: 10.1001/archneur.1995.00540280029015
– ident: e_1_3_3_21_2
  doi: 10.1093/oxfordjournals.aje.a113955
– ident: e_1_3_3_22_2
  doi: 10.1093/oxfordjournals.aje.a116946
– ident: e_1_3_3_19_2
  doi: 10.1016/S0140-6736(99)01013-2
– ident: e_1_3_3_28_2
  doi: 10.1056/NEJM199607043350102
– ident: e_1_3_3_25_2
  doi: 10.1182/blood.V89.8.2817
– ident: e_1_3_3_1_2
  doi: 10.1161/str.26.3.361
– ident: e_1_3_3_14_2
  doi: 10.1136/bmj.312.7023.83
– volume: 2
  start-page: 1191.
  year: 1962
  ident: e_1_3_3_2_2
  publication-title: BMJ
– ident: e_1_3_3_12_2
  doi: 10.1016/S0140-6736(95)91928-7
– ident: e_1_3_3_11_2
  doi: 10.1016/S0140-6736(95)91926-0
SSID ssj0002385
Score 2.13677
Snippet Background and Purpose — Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie,...
Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the...
BACKGROUND AND PURPOSE: Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie,...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1202
SubjectTerms Adolescent
Adult
Arterial Occlusive Diseases - epidemiology
Arterial Occlusive Diseases - etiology
Biological and medical sciences
Brain Ischemia - epidemiology
Brain Ischemia - etiology
Case-Control Studies
Comorbidity
Contraceptives, Oral - adverse effects
Desogestrel - adverse effects
Dose-Response Relationship, Drug
Female
Humans
Levonorgestrel - adverse effects
Medical sciences
Middle Aged
Netherlands - epidemiology
Neurology
Norpregnenes - adverse effects
Odds Ratio
Risk Assessment
Risk Factors
Stroke - epidemiology
Stroke - etiology
Surveys and Questionnaires
Thrombosis - epidemiology
Thrombosis - etiology
Vascular diseases and vascular malformations of the nervous system
Subtitle Oral Contraceptives and the Risk of Ischemic Stroke
Title Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study
URI https://www.ncbi.nlm.nih.gov/pubmed/11988591
https://www.proquest.com/docview/197838839
https://www.proquest.com/docview/71643592
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1di9NAFB3qCiKI-G1dXefBB6Wkm0kmX75tZZdFreJuF_YtJJMZKLpJSVMffPPf-DO9d2aSNLCF1ZdQkmYCuSc3d07OPUPIm7iIilDlyolQ4cql7zm5CFwnhoQZc5WoWCHfMf8Snl7wj5fB5Wj0Z0u1tGnyqfh1bV_J_0QV9kFcsUv2HyLbDQo74DfEF7YQYdjeKMZnVhd-hLrMpe60r6urvEKTkWXZCd2wvvxaa5YAqVwtZPlp6FZNUSEzoG1mtadErR1DBn9sVZatDn0JU2Itql83dfV9ICY613u0_VMSuVs8wyeJFLltBZFZKZueiF1kpbE6mMmsp22xswqy4mRWrc16VXNjgTTBXvqO3p4h82FIJL3-9OTz5NiO3JIZXi8dnEqbgD3uYL_sdoY2VhkWicFWumWebte-5j0QMt3bMD1fnBmLSsjsPJhC8eLxqZFMbgFkdaURwlgSo59f_27sFIvtoVvkthdBlYaf_7_1vvRQ-ATW0hYufbj7wmhSa4caVEL3VtkaHkplVlPZPd3RZc_iAblv5yv0yIDvIRnJ8hG5M7eKjMfkN2KQVoq2GKQ9BumypC0GaVNRxCAdYpC-1Qh8RzX-3lNEHx2ijwL6KKCP1vZKLfqoQd8TcnFyvPhw6thlPRzhc7dxRCh44UmGaw-oHEpQ7uUsKAoBM_eEcxmFIvaLgiXCzZmIAxXg11sJKcSPC08o_ynZK6tSPie0kELyKEokzwOeKzeXBWfcLZRIMj_M3DFJ2lucCut5j0uv_Ej13DdkqctSiFTaRyrVkUr9kzHxu3NXxvnlRmcdDCLZn-qjc2fgj8l-G9rUppJ1ypCAjWGuMiavu6OQ5_HjHTyQ1WadIq_hB4k3Js8MHvqRLZ5e7DyyT-72D9tLstfUG_kKaukmP9Aw_gttcsDH
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+Arterial+Thrombosis+in+Relation+to+Oral+Contraceptives+%28RATIO%29+study%3A+oral+contraceptives+and+the+risk+of+ischemic+stroke&rft.jtitle=Stroke+%281970%29&rft.au=Kemmeren%2C+Jeanet+M&rft.au=Tanis%2C+Bea+C&rft.au=van+den+Bosch%2C+Maurice+A+A+J&rft.au=Bollen%2C+Edward+L+E+M&rft.date=2002-05-01&rft.eissn=1524-4628&rft.volume=33&rft.issue=5&rft.spage=1202&rft_id=info:doi/10.1161%2F01.STR.0000015345.61324.3F&rft_id=info%3Apmid%2F11988591&rft.externalDocID=11988591
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon